Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
05/2009
05/07/2009WO2009056569A1 Lh liquid formulations
05/07/2009WO2009055860A1 Transdermal delivery system
05/07/2009WO2009055859A1 Transdermal delivery system for hormones and steroids
05/07/2009WO2009024287A3 Azoloraine derivatives, method for the production thereof, pharmaceuticals containing these compounds, and the use thereof
05/07/2009US20090118475 Clostridial Neurotoxin Compositions and Modified Clostridial Neurotoxins
05/07/2009US20090118250 Pharmaceutical composition
05/07/2009US20090118236 such as 2-[(3,5-dimethyl-4-(4'-hydroxy-3'-iso-propylbenzyl) phenoxy)methyl]-4-(3-chlorophenyl)-2-oxo-2 lambda 5-[1,3,2]-dioxaphosphonane, used for preventing and/or treating metabolic disorders such as obesity, hypercholesterolemia and hyperlipidemia
05/07/2009US20090118182 Fibroblast Growth Factor-Like Polypeptides
05/07/2009US20090117193 Compositions Comprising an Active Agent
05/07/2009US20090117064 Stable vitamin b6 derivative
05/07/2009DE4042752B4 Verfahren zur Herstellung von Mikropartikeln, welche einen Wirkstoff in einem bioabbaubaren polymeren Träger enthalten Process for the preparation of microparticles containing an active agent in a biodegradable polymeric carrier,
05/07/2009CA2704117A1 Transdermal delivery system
05/07/2009CA2704116A1 Transdermal delivery system for hormones and steroids
05/07/2009CA2700662A1 Lh liquid formulations
05/06/2009EP2055302A1 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
05/06/2009EP1807065A4 Methods and compositions for treating nephrogenic diabetes insipidus
05/06/2009EP1667678B1 Animal feed composition
05/06/2009EP1443961B1 Glycoprotein compositions
05/06/2009CN101426806A Oxa-steroids derivatives as selective progesterone receptor modulators
05/06/2009CN101426763A Sulfide and disulfide compounds and compositions for cholesterol management and related uses
05/06/2009CN101426488A Stable oral pharmaceutical composition containing thyroid hormone receptor agonists
05/06/2009CN101423551A Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded; and uses thereof
05/06/2009CN101423500A Substituted benzoxazoles and analogues as estrogenic agents
05/06/2009CN101422541A Medicine for preventing and treating chronic lymphocytic thyroiditis
05/06/2009CN101422486A Velvet antler insulin active factor extraction method
05/06/2009CN100484934C Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
05/06/2009CN100484569C Medicament for mobilizing pluripotent stem cells from tissue into peripheral blood
05/05/2009US7527968 Administering cells from bone marrow, peripheral blood, umbilical cord blood or placenta; pancreatic damage
04/2009
04/30/2009WO2009054423A1 Oxadiazolidinedione compound
04/30/2009WO2009054390A1 Thiazolidinedione compound
04/30/2009WO2009053716A1 Purine derivatives useful as pi3 kinase inhibitors
04/30/2009US20090111831 Pharmaceutical compositions
04/30/2009US20090111744 Human Growth Gene and Short Stature Gene Region
04/30/2009CA2703793A1 Oxadiazolidinedione compound
04/30/2009CA2703138A1 Purine derivatives useful as pi3 kinase inhibitors
04/29/2009EP2052725A2 Use of lanthanum compounds for the treatment of bone diseases
04/29/2009EP1727555B1 Production of hop extracts having oestrogenic and antiproliferative bioactivity
04/29/2009EP1485072B1 Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
04/29/2009EP1399133B1 Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
04/29/2009EP1313482B1 Pharmaceutical composition and method for treating hypogonadism
04/29/2009EP1218509B1 Fibroblast growth factor-like polypeptides
04/29/2009CN101421290A 17-phosphorous steroid derivatives useful as progesterone receptor modulators
04/29/2009CN101421279A Imidazo compounds
04/29/2009CN101421273A Spiro-imidazo compounds
04/29/2009CN101418001A Dipeptidase-IV inhibitor sulfonyl urea derivates
04/29/2009CN101418000A DPP-IV inhibitor derivates containing benzofuran sulfonyl ureas
04/29/2009CN101417988A Biguanide piperazines dipeptidyl peptidase IV inhibitor
04/29/2009CN101416949A Pharmaceutical compositions of estrogenic agents
04/29/2009CN100482686C Treatment for diabetes
04/29/2009CN100482281C Method of treatment using anti-ErbB antibody-maytansinoid conjugates
04/29/2009CN100482276C Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
04/29/2009CN100482233C Compositions and methods for treating amyloidosis
04/28/2009US7524970 Compounds
04/28/2009US7524873 Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis
04/28/2009US7524847 Inhibit Dipeptidyl peptidase-IV; 7-(2-Butynyl)-3-methyl-3,7-dihydropurine-2,6-dione; suppress degradation of Glucagon-Like Peptide-1; enhance action of incretin; facilitate insulin secretion from pancreatic beta -cells due to glucose stimulus; postchallenge hyperglycemia, improved oral glucose tolerance
04/28/2009US7524834 Antiinflammatory and antiallergic glucocorticosteroid, sterile glucocorticosteroids
04/28/2009US7524649 Chimeric polypeptide having a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; treating giantism; acromegaly; cancer diabetic retinopathy; diabetic nephropathy, diabetic complications and any disease of growth hormone excess
04/28/2009CA2416311C 16alpha-methyl or ethyl substituted estrogens
04/28/2009CA2410220C 16, 17-carbocyclic condensed steroid compounds having selective estrogenic activity
04/28/2009CA2361424C Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
04/28/2009CA2360236C Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
04/28/2009CA2339765C Compounds and compositions for delivering active agents
04/28/2009CA2259922C Calcium receptor active compounds
04/23/2009WO2009050200A1 Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators
04/23/2009WO2009050197A2 Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
04/23/2009WO2008152094A3 Substituted acetamides as modulators of the ep2 receptor
04/23/2009US20090105349 alopecia, prostate cancer, livestock growth, acne; use of 4-aryloxybenzonitriles such as 3-Chloro-4-(2-ethylsulfanyl-phenoxy)-benzonitrile or 4-(2,6-Difluoro-phenoxy)-2-trifluoromethyl-benzonitrile
04/23/2009US20090105333 Melatonin agonist treatment
04/23/2009US20090105163 Conjugates of Immune Cell Specific Macrolide Compounds with Anti-Inflammatory Compounds for Improved Cellular Targeting of Anti-Inflammatory Therapy
04/23/2009US20090105134 C-Terminally Pegylated Growth Hormones
04/23/2009US20090104230 Compositions and methods of using capsid protein from flaviviruses and pestiviruses
04/22/2009EP2050443A1 Reduction of breast density with 4-hydroxy tamoxifen
04/22/2009EP2049149A2 Pegylated extended insulins
04/22/2009EP2049148A1 A stable liquid formulation of human growth hormone
04/22/2009EP2049108A1 Treatment of endocrine dysfunction using iron chelators
04/22/2009EP2049104A2 Pyrrolidinone anilines as progesterone receptor modulators
04/22/2009EP1931654B1 Modulators of metabolism and the treatment of disorders related thereto
04/22/2009EP1572171B1 Reduction of breast density with 4-hydroxy tamoxifen
04/22/2009EP1568768B1 PROTEIN BINDING TO Akt2
04/22/2009EP1507529B1 Combination comprising valsartan, amlodipine and hydrochlorothiazide
04/22/2009CN101415720A 11-phosphorous steroid derivatives useful as progesterone receptor modulators
04/22/2009CN101415710A Bicyclic imidazole or thiadiazole heterocycles useful as selective androgen receptor modulators
04/22/2009CN101415419A Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
04/22/2009CN100480258C Purified LH (Luteinizing hormone)
04/22/2009CN100479856C Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
04/21/2009US7521455 Histamine H3 receptor antagonist or inverse agonist activity; metabolic diseases, circulatory diseases, or nervous system diseases; e.g. 3-(4-((1-cyclobutyl-4-piperidinyl)oxy)phenyl)-2-ethylpyrido(2,3-d)pyrimidin-4(3H)-one
04/21/2009US7521070 Powder of ossified horns of reindeer and containing endorphins in the form of agent for preventing and treating pathological states associated with endorphin deficiency; drug abuse, drug dependence
04/21/2009US7521053 Angiopoietin-2 specific binding agents
04/21/2009CA2400317C Improved paste formulations
04/21/2009CA2338358C Compounds and compositions for delivering active agents
04/21/2009CA2182034C Treatment for juvenile diabetes
04/16/2009WO2009047343A1 Benzocycloheptene derivatives as estrogens having selective activity
04/16/2009WO2009047330A1 Use of wnt5a for treating or preventing obesity and atherosclerosis
04/16/2009WO2009027994A3 NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3β-OL
04/16/2009WO2009020234A3 Pyrrolidin-2 -one derivatives as androgen receptor modulator
04/16/2009WO2005042727A3 Methods of organ regeneration
04/16/2009US20090099250 Benzocycloheptene derivatives as estrogens having selective activity
04/16/2009US20090099241 Pharmaceutical composition containing antihypertensive agents
04/16/2009US20090099223 Methods of treating hormone-related conditions using thio-oxindole derivatives
04/16/2009US20090099100 Compositions and methods for treating amyloidosis
1 ... 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 ... 290